Valerie Sapozhnikova

Cooley advised the underwriters of Viking Therapeutics – a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders – on its $632.5 million public offering of common stock.

Cooley advised Lantheus Holdings, a top publicly traded radiopharmaceutical-focused company, on a concurrent private investment in public equity (PIPE) transaction, partnering transaction and asset sale with Perspective Therapeutics.

Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering.

Cooley advised Turnstone Biologics, a clinical-stage biotechnology company, on its upsized $80 million initial public offering.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.